It is my understanding that GNBT and NGIO are separate companies, so NGIO needs to file an S1 and the $50M funding from Oasis takes care of going concern on ngio. If the form 10 had been “cleared” and completed, there should be nothing holding back filing the S1. Unless they want some good news to support the stock price or justify it upon listing.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.